Advertisement

Topics

FDA Grants Orphan Drug Designation to PharmaMar’s Lurbinectedin for Treatment of Small Cell Lung Cancer

10:22 EDT 3 Aug 2018 | Speciality Pharma Journal

PharmaMar (MCE: PHM) announces that lurbinectedin has been granted orphan drug status by the FDA for the treatment of small cell lung cancer. The FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than …

Original Article: FDA Grants Orphan Drug Designation to PharmaMar’s Lurbinectedin for Treatment of Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Orphan Drug Designation to PharmaMar’s Lurbinectedin for Treatment of Small Cell Lung Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...